Analysts predict that Boston Scientific Corporation (NYSE:BSX) will report sales of $2.35 billion for the current fiscal quarter, Zacks reports. Ten analysts have made estimates for Boston Scientific’s earnings, with the lowest sales estimate coming in at $2.32 billion and the highest estimate coming in at $2.36 billion. Boston Scientific reported sales of $2.19 billion in the same quarter last year, which indicates a positive year over year growth rate of 7.3%. The company is expected to announce its next quarterly earnings report on Thursday, February 1st.

On average, analysts expect that Boston Scientific will report full-year sales of $2.35 billion for the current year, with estimates ranging from $8.96 billion to $9.01 billion. For the next financial year, analysts expect that the firm will report sales of $9.58 billion per share, with estimates ranging from $9.41 billion to $9.71 billion. Zacks’ sales calculations are an average based on a survey of analysts that cover Boston Scientific.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.31. The firm had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. Boston Scientific’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.27 EPS.

A number of brokerages recently weighed in on BSX. BMO Capital Markets reiterated a “buy” rating and set a $31.00 price target on shares of Boston Scientific in a research note on Wednesday, November 29th. Cowen set a $31.00 price target on shares of Boston Scientific and gave the stock a “buy” rating in a research note on Thursday, November 30th. SunTrust Banks set a $33.00 price target on shares of Boston Scientific and gave the stock a “buy” rating in a research note on Monday. Oppenheimer reiterated a “hold” rating on shares of Boston Scientific in a research note on Wednesday, November 29th. Finally, BTIG Research upgraded shares of Boston Scientific from a “neutral” rating to a “buy” rating and set a $31.00 price target for the company in a research note on Thursday, November 30th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $30.97.

In other Boston Scientific news, EVP Supratim Bose sold 347,137 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $29.12, for a total transaction of $10,108,629.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy A. Pratt sold 11,061 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $29.24, for a total transaction of $323,423.64. Following the transaction, the executive vice president now owns 174,681 shares of the company’s stock, valued at $5,107,672.44. The disclosure for this sale can be found here. Insiders have sold a total of 424,698 shares of company stock valued at $12,273,553 over the last 90 days. 0.74% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Comerica Securities Inc. boosted its position in shares of Boston Scientific by 0.9% in the second quarter. Comerica Securities Inc. now owns 11,478 shares of the medical equipment provider’s stock worth $318,000 after acquiring an additional 99 shares during the last quarter. ETRADE Capital Management LLC boosted its position in shares of Boston Scientific by 1.7% in the second quarter. ETRADE Capital Management LLC now owns 10,079 shares of the medical equipment provider’s stock worth $279,000 after acquiring an additional 171 shares during the last quarter. Krilogy Financial LLC boosted its position in shares of Boston Scientific by 5.9% in the second quarter. Krilogy Financial LLC now owns 7,680 shares of the medical equipment provider’s stock worth $213,000 after acquiring an additional 430 shares during the last quarter. Wetherby Asset Management Inc. boosted its position in shares of Boston Scientific by 3.9% in the second quarter. Wetherby Asset Management Inc. now owns 13,788 shares of the medical equipment provider’s stock worth $382,000 after acquiring an additional 523 shares during the last quarter. Finally, Greenwood Capital Associates LLC boosted its position in shares of Boston Scientific by 1.1% in the second quarter. Greenwood Capital Associates LLC now owns 53,330 shares of the medical equipment provider’s stock worth $1,478,000 after acquiring an additional 564 shares during the last quarter. Institutional investors and hedge funds own 90.57% of the company’s stock.

Shares of Boston Scientific (NYSE BSX) opened at $24.94 on Wednesday. The firm has a market cap of $34,320.00, a price-to-earnings ratio of 21.43, a P/E/G ratio of 2.02 and a beta of 0.95. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. Boston Scientific has a 52 week low of $20.36 and a 52 week high of $29.93.

COPYRIGHT VIOLATION WARNING: “$2.35 Billion in Sales Expected for Boston Scientific Corporation (BSX) This Quarter” was first published by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2017/12/06/2-35-billion-in-sales-expected-for-boston-scientific-corporation-bsx-this-quarter.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Get a free copy of the Zacks research report on Boston Scientific (BSX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.